An Open Label Study of GBT440 to Evaluate the Effect on Oxygenation in Healthy Subjects at Rest and Maximal Exercise Under Hypoxic Conditions
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs GBT 440 (Primary)
- Indications Hypoxia; Idiopathic pulmonary fibrosis; Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms Basecamp Study
- Sponsors Global Blood Therapeutics
- 29 Sep 2017 Planned number of patients changed from 12 to 20.
- 29 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 17 Feb 2017 New trial record